Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2023-01-01 DOI:10.1097/WNF.0000000000000533

Qiang Deng, Sihong Tao, Hui Huang, Qikun Lv, Wei Wang

{"title":"Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies.","authors":"Qiang Deng, Sihong Tao, Hui Huang, Qikun Lv, Wei Wang","doi":"10.1097/WNF.0000000000000533","DOIUrl":null,"url":null,"abstract":"Introduction: Chloroquine supplementation may show some potential in improving the efficacy for glioblastoma, and this meta-analysis aimed to identify the efficacy of chloroquine supplementation for patients with glioblastoma.Methods: Several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases have been systematically searched through August 2022, and we included randomized controlled trials assessing the efficacy of chloroquine supplementation for glioblastoma. This meta-analysis was performed using the random-effect model or fixed-effect model based on the heterogeneity.Results: Four randomized controlled trials were finally included in this meta-analysis. In comparison with control group for glioblastoma, chloroquine supplementation was associated with substantially decreased mortality (odd ratio [OR], 0.17; 95% confidence interval [CI], 0.06-0.53; P = 0.002), improved survival time (mean difference, 15.63; 95% CI, 2.27-28.99; P = 0.02), and remission (OR, 15.63; 95% CI, 2.27-28.99; P = 0.02), but unraveled no obvious impact on the incidence of adverse events (OR, 3.27; 95% CI, 0.29-36.44; P = 0.34) or seizure (OR, 2.57; 95% CI, 0.05-127.68; P = 0.64).Conclusions: Chloroquine supplementation may be effective to improve the treatment efficacy for glioblastoma.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 1","pages":"1-5"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000533","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chloroquine supplementation may show some potential in improving the efficacy for glioblastoma, and this meta-analysis aimed to identify the efficacy of chloroquine supplementation for patients with glioblastoma.

Methods: Several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases have been systematically searched through August 2022, and we included randomized controlled trials assessing the efficacy of chloroquine supplementation for glioblastoma. This meta-analysis was performed using the random-effect model or fixed-effect model based on the heterogeneity.

Results: Four randomized controlled trials were finally included in this meta-analysis. In comparison with control group for glioblastoma, chloroquine supplementation was associated with substantially decreased mortality (odd ratio [OR], 0.17; 95% confidence interval [CI], 0.06-0.53; P = 0.002), improved survival time (mean difference, 15.63; 95% CI, 2.27-28.99; P = 0.02), and remission (OR, 15.63; 95% CI, 2.27-28.99; P = 0.02), but unraveled no obvious impact on the incidence of adverse events (OR, 3.27; 95% CI, 0.29-36.44; P = 0.34) or seizure (OR, 2.57; 95% CI, 0.05-127.68; P = 0.64).

Conclusions: Chloroquine supplementation may be effective to improve the treatment efficacy for glioblastoma.

查看原文本刊更多论文

补充氯喹治疗胶质母细胞瘤:随机对照研究的荟萃分析。

简介:补充氯喹可能具有提高胶质母细胞瘤疗效的潜力，本荟萃分析旨在确定补充氯喹对胶质母细胞瘤患者的疗效。方法:系统检索PubMed、Embase、Web of Science、EBSCO和Cochrane图书馆数据库等多个数据库，并纳入评估补充氯喹治疗胶质母细胞瘤疗效的随机对照试验。基于异质性，采用随机效应模型或固定效应模型进行meta分析。结果:四项随机对照试验最终纳入本荟萃分析。与胶质母细胞瘤对照组相比，补充氯喹可显著降低死亡率(奇比[OR]， 0.17;95%置信区间[CI]， 0.06-0.53;P = 0.002)，延长生存时间(平均差异15.63;95% ci, 2.27-28.99;P = 0.02)，缓解(OR, 15.63;95% ci, 2.27-28.99;P = 0.02)，但对不良事件发生率无明显影响(OR, 3.27;95% ci, 0.29-36.44;P = 0.34)或癫痫发作(or, 2.57;95% ci, 0.05-127.68;P = 0.64)。结论:补充氯喹可有效提高胶质母细胞瘤的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.